Skip to content
15% off your first order15% off your first order

CJC-1295 vs Ipamorelin

CJC-1295 and Ipamorelin are both peptides studied for their effects on growth hormone release, but they act through different receptor pathways. CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone (GHRH) analog with a short half-life. Research associates its brief action with preserving natural pulsatile release. Ipamorelin is a selective growth-hormone secretagogue that acts as a ghrelin receptor agonist, studied for releasing growth hormone with minimal cortisol or prolactin response. Published human data on CJC-1295 come mainly from small clinical studies of its long-acting DAC form. Ipamorelin's primary studies are animal work on growth hormone release and bone growth. Human safety data remain limited for both.